Biotest Future Growth
Future criteria checks 1/6
Biotest is forecast to grow earnings and revenue by 64.7% and 8.2% per annum respectively while EPS is expected to grow by 65.4% per annum.
Key information
64.7%
Earnings growth rate
65.4%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 8.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 623 | -3 | -43 | N/A | 1 |
12/31/2023 | 578 | -29 | -63 | N/A | 2 |
12/31/2022 | 528 | -34 | -27 | N/A | 2 |
6/30/2022 | 511 | -65 | 30 | 49 | N/A |
3/31/2022 | 512 | -54 | 51 | 69 | N/A |
12/31/2021 | 516 | -63 | 16 | 34 | N/A |
9/30/2021 | 514 | -28 | -3 | 24 | N/A |
6/30/2021 | 507 | -33 | -32 | -5 | N/A |
3/31/2021 | 507 | -35 | -49 | -22 | N/A |
12/31/2020 | 484 | -31 | -44 | -17 | N/A |
9/30/2020 | 466 | -34 | -74 | -40 | N/A |
6/30/2020 | 459 | -24 | -83 | -49 | N/A |
3/31/2020 | 439 | -15 | -70 | -36 | N/A |
12/31/2019 | 419 | -5 | -68 | -34 | N/A |
9/30/2019 | 406 | -9 | -74 | -19 | N/A |
6/30/2019 | 395 | -3 | -61 | -6 | N/A |
3/31/2019 | 390 | -6 | -81 | -26 | N/A |
12/31/2018 | 400 | -13 | -105 | -50 | N/A |
9/30/2018 | 405 | 18 | -123 | -16 | N/A |
6/30/2018 | 409 | 6 | -100 | 6 | N/A |
3/31/2018 | 400 | 1 | -92 | 15 | N/A |
12/31/2017 | 378 | -16 | -72 | 34 | N/A |
9/30/2017 | 257 | -48 | -125 | 8 | N/A |
6/30/2017 | 301 | -47 | -141 | -8 | N/A |
3/31/2017 | 340 | -29 | -98 | 35 | N/A |
12/31/2016 | 408 | 6 | -67 | 66 | N/A |
9/30/2016 | 531 | 128 | -43 | 51 | N/A |
6/30/2016 | 525 | 52 | -37 | 57 | N/A |
3/31/2016 | 526 | 36 | N/A | 44 | N/A |
12/31/2015 | 535 | 27 | N/A | 38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BTTA.Y is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BTTA.Y is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BTTA.Y is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BTTA.Y's revenue (8.2% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: BTTA.Y's revenue (8.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BTTA.Y's Return on Equity is forecast to be high in 3 years time